Use of the Control of Allergic Rhinitis and Asthma Test and pulmonary function tests to assess asthma control in pregnancy by Amaral, Luís et al.
Aust N Z J Obstet Gynaecol. 2018 Feb;58(1):86-90. doi: 10.1111/ajo.12673. Epub 2017 Jul 27. 
Use of the Control of Allergic Rhinitis and Asthma 
Test and pulmonary function tests to assess asthma 
control in pregnancy. 




Asthma is one of the most prevalent chronic medical conditions to complicate 
pregnancy. Similarly, active management strategies that prioritise asthma control in this 
vulnerable population can have a far‐reaching impact. 
Aim 
To describe lung function parameters and results of the Control of Allergic Rhinitis and 
Asthma Test (CARAT) questionnaire in pregnant asthmatics and to analyse correlations 
between lung function tests and CARAT results. 
Methods 
All pregnant asthmatics who performed spirometry and CARAT between September 
2014 and August 2015 were included. A medical records review was performed and 
data regarding demographics, sensitisation and medical prescriptions were recorded. 
Control of asthma and rhinitis was defined by CARAT total score (CARAT (T)) ≥ 24; 
upper airways (U) control if CARAT (U) > 8; lower airways (L) control if CARAT 
(L) > 15. 
Results 
Forty‐two pregnant asthmatics were included, with a median age (interquartile range)of 
32 (27–34) years; all had a previous medical diagnosis of asthma and rhinitis, 76% were 
atopic, 94% sensitised to dust mites and 43% were polissensitised. More than 80% 
presented poor control (CARAT (T) < 24) in the first assessment and 15% had a 
percentage forced expiratory volume in the first second < 80%. There were significant 
negative correlations between CARAT (L) and CARAT (T) scores and step‐up of 
controller medication, (correlation coefficients  = −0.453 and −0.392, respectively). 
Conclusion 
The use of tools such as spirometry and validated questionnaires to objectively assess 
asthma control during pregnancy should be routinely applied to assist in the 
management of these patients. These data reinforce the importance of close monitoring 
of pregnant asthmatics to achieve and maintain better disease control. 
Introduction 
Asthma is one of the most common chronic diseases of women of 
childbearing age,1complicating up to 8% of pregnancies in the United 
States2 and 12% in Australia.3 
The course of asthma during pregnancy is unpredictable. Generally, asthma 
worsens during pregnancy in approximately one‐third of women, one‐third 
improves and the other third remains unchanged.4 
Maternal asthma is associated with a higher rate of adverse perinatal 
outcomes, including intrauterine growth restriction (IUGR), preterm delivery 
and preeclampsia.5, 6 Moreover, asthma exacerbations are associated with an 
increased risk of any congenital malformation.7 On the other hand, when 
properly controlled, asthma is associated with a favourable fetal and maternal 
prognosis and well‐controlled asthma is fundamental for an uncomplicated 
pregnancy and a healthy newborn.3 A subjective assessment of asthma control 
has little benefit in the discrimination of controlled and uncontrolled patients 
and this may lead to insufficient treatment or excessive use of medication.8 
In pregnant women, shortness of breath is the most common respiratory 
complaint. Nonetheless, this is not associated with other typical asthma 
symptoms such as wheezing, chest tightness and cough.9 Thus, asthma 
control evaluation in pregnant asthmatics, may be a challenge for clinicians 
because of the many physiological peculiarities associated with the pregnancy 
itself. 
According to the Global Initiative for Asthma (GINA), control is based on 
asthma symptoms, limitation on daily life activities, nocturnal 
symptoms/awakenings, exacerbations with the need of rescue medication and 
lung function tests (forced expiratory volume in the first second (FEV1)).10 
In order to achieve and maintain asthma control in pregnancy, regular 
assessment and appropriate treatment of asthma and concomitant diseases that 
can affect the control is necessary. Allergic rhinitis (AR) is frequently 
associated with asthma and its control. According to the Allergic Rhinitis and 
its Impact on Asthma (ARIA) recommendations, the management of these 
two conditions must be held jointly.11, 12 However, the tools available to 
objectively evaluate AR control are scarce. 
The Control of Allergic Rhinitis and Asthma Test (CARAT) is the only 
validated self‐administered questionnaire that evaluates asthma and AR 
control concurrently and it was developed in Portugal.13 The first study that 
assessed the association between the results of the CARAT questionnaire and 
spirometry parameters, performed in adults with asthma and/or AR, 
demonstrated a weak correlation between CARAT scores and percentage of 
predicted FEV1 (%FEV1).14 To our knowledge, no study has evaluated the 
association of CARAT scores and spirometry in pregnant asthmatics. 
The primary aim of this study was to describe the lung function parameters 
and the results of the CARAT questionnaire in a series of pregnant women 
with asthma and/or AR. As a secondary objective, we sought to analyse 
possible associations between CARAT scores and spirometric data during 
pregnancy. 
Materials and Methods 
This was a longitudinal study, including pregnant women with asthma and AR 
followed in an Allergy and Clinical Immunology Department. 
Pregnant asthmatics were selected based on the data of lung function tests 
carried out between September 2014 and August 2015. During this period, all 
pregnant women who underwent spirometry, were invited to complete the 
CARAT. Inhaler technique was assessed at each evaluation. Lung function 
parameters (%FEV1), spirometry classification, demographic and 
anthropometric characteristics (age, body mass index (BMI)) and CARAT 
results were collected. A medical records review was performed and clinical 
data regarding clinical diagnosis, atopic sensitisation, smoking habits, acid 
reflux, need of rescue and step up of control medication were recorded. The 
CARAT is a self‐administered questionnaire assessing asthma and AR control 
in the last 4 weeks. It is composed of 10 questions divided into two scores: 
score 1 (CARAT (U)), made up of four questions regarding symptoms of the 
upper airways and score 2 (CARAT (L)), including four questions specifically 
related to lower airways symptoms, one sleep‐related symptoms and one with 
additional medication (evaluated jointly).13 The question regarding 
medication had three response options (‘Never’ – three points, ‘Less than 
seven days’ – two points ‘More than seven days’ – 0 points) and an option 
‘I'm not taking any medication’ which was also attributed three points. All the 
questions are scored on a Likert scale of four points and the total score 
CARAT (T) can vary between 0 and 30 points, corresponding to the worst and 
best possible control, respectively. The partial scores score 1 CARAT (U) of 
more than eight points, the score 2 CARAT (L) greater than 15 points and the 
total score CARAT (T) greater than 24, are indicative of good control. 
Spirometry was performed according to the European Respiratory 
Society/American Thoracic Society (ERS/ATS) guidelines15 using a Jaeger 
spirometer, MasterScope (VIASYS Healthcare, Hoechberg, Germany). 
Spirometry was classified as normal, small airway obstruction (with normal 
FEV1), restrictive ventilatory defects, mixed ventilatory defects and mild 
obstructive (FEV1 ≥ 70%), moderate (50% ≤ FEV1 < 70%) and severe 
(FEV1 < 50%). Classification of obstructive ventilatory defects was based on 
the FEV1and the forced vital capacity ratio (FEV1/FVC), and a ratio 
FEV1/FVC < 70% indicates airway obstruction. 
Study population 
All pregnant women who underwent spirometry during the study period were 
included. Those with only one lung function assessment were excluded 
(Fig. 1). 
Figure 1 
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Participant selection flowchart.
Statistical analysis
Statistical analysis was performed using SPSS version 22 (IBM, Armonk, NY, 
USA). Appropriate descriptive measures
standard deviation for continuous variables with normal distribution and 
median and interquartile ranges (IQR) for continuous variables with 
non‐normal distribution. The 
Student's‐t test in comparison of means in independent samples.
The correlations between the results of CARAT, %FEV1 and the need for 
therapeutic step‐up were calculated using Spearma
coefficient. A P=value below 0.05 was considered statistically significant.
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dust mites, 16 (50%) to pollens, 9 (28%) cat and/or dog dander and 18 (43%) 
were polysensitised (Table 1). 
Table 1. Patients’ clinical characteristics 
Age, median (IQR), years 32 (27–34) 
Body mass index at first assessment 
Underweight (<20) 1 (2) 
Normal range (20–25) 13 (31) 
Overweight (25–30) 18 (43) 
Obesity (>30) 10 (24) 
Diagnosis 
Asthma and rhinitis 42 (100) 
Atopic dermatitis 4 (10) 
Urticaria 2 (5) 
Atopy 
Age, median (IQR), years 32 (27–34) 
Non‐atopic 4 (10) 
Atopic 32 (76) 
Dust mites 30 (94) 
Pollens 16 (50) 
Animal dander 9 (28) 
Polysensitised 18 (43) 
Undetermined 6 (14) 
Treatment (first assessment) 
No treatment 14 (33) 
Inhaled corticosteroids 27 (64) 
Long‐acting Beta‐2 agonists 11 (26) 
Age, median (IQR), years 32 (27–34) 
Leukotriene antagonists 5 (12) 
Intra‐nasal corticosteroids 6 (14) 
Oral anti‐histamines 31 (74) 
• IQR, interquartile range. 
• Data are presented as n (%), unless stated otherwise. 
At the first observation, 10 (24%) were obese (BMI > 30). Fourteen (33%) did 
not have any controller medication for asthma and rhinitis, 27 (64%) used 
inhaled corticosteroids, six (14%) used topical nasal steroids and 31 (74%) 
were medicated with antihistamines for exacerbations (Table 1). 
Of the 14 women without controller medication, 64% reported that they were 
not on any medication because of fear of harm to the fetus and 36% were 
advised to interrupt their medication by the doctor who was monitoring the 
pregnancy. 
In the first evaluation, almost 15% of the pregnant patients had 
%FEV1 < 80% and approximately 30% had an abnormal spirometry. In these, 
almost 17% presented moderate obstruction and none had severe obstruction 
or mixed/restrictive ventilatory defects. The spirometry classification, 
performed throughout the different assessments during the pregnancy 
remained constant (Table 2). 
Table 2. Pulmonary function tests (PFT) and control during pregnancy 
 First assessment 
(n = 42) 
Second 
Assessment 
(n = 42) 
Third 
Assessment 
(n = 22) 
Gestational age (weeks), 
median (IQR) 
18 (13–24) 28 (22–33) 29 (25–35) 
%FEV1, mean (SD) 97,2 (13,4) 98,9 (13,4) 97,3 (16,1) 
PFT classification 
Normal 30 (71,4) 29 (69) 13 (59,1) 
Mild obstruction 9 (21,4) 10 (23,8) 7 (31,8) 
Moderate obstruction 2 (4,8) 1 (2,4) – 
Small airway 
obstruction 
1 (2,4) 2 (4,8) 2 (9,1) 
CARAT (U) 
Score, mean (SD) 5,8 (3,2) 7,2 (2,9) 7,6 (3,3) 
Uncontrolled 31 (74) 24 (57,1) 10 (45,5) 
 First assessment 
(n = 42) 
Second 
Assessment 
(n = 42) 
Third 
Assessment 
(n = 22) 
CARAT (L) 
Score, mean (SD) 11,9 (4,9) 13,4 (4,6) 14,4 (4,1) 
Uncontrolled 30 (71) 23 (54,8) 12 (54,5) 
CARAT (T) 
Score, mean (SD) 17,7 (7,4) 20,6 (6,3) 22,0 (7,0) 
Uncontrolled 34 (81,0) 30 (71,4) 11 (50,0) 
Step up medication – 4 (9,5) – 
• CARAT (L), Control of Allergic Rhinitis and Asthma Test (lower airways); 
CARAT (T), CARAT (total); CARAT (U), CARAT (upper airways); IQR, 
interquartile range; %FEV1, percentage of forced expiratory volume in the 
first second; SD, standard deviation. 
• Data are presented as n (%), unless stated otherwise. 
At the first visit, the assessment of the upper airway symptoms using CARAT 
(U) score showed poor control in 74% and the scores of the lower respiratory 
tract symptoms according to CARAT (L) also showed poor control in 71%. A 
significant improvement in the second evaluation was observed (P = 0.01). 
Correlations between the CARAT scores and %FEV1 results were not 
statistically significant. On the other hand, significant negative correlations 
were found between the scores of CARAT (L) and CARAT (T) and the need 
for stepping up controller medication (correlation coefficient 
(CC) = −0.453, P = 0.003) and CC = −0.392; P = 0.01, respectively). None of 
the pregnant asthmatics required oral corticosteroids for exacerbations. 
Eighteen pregnant women (43%) complained of having an acid taste in the 
mouth and regurgitation at least 1 day per week, particularly in the third 
trimester. All reported controlling these symptoms with dietary and lifestyle 
changes without pharmacological treatment. Further comparison revealed no 
significant differences between acid‐reflux symptoms and asthma 
exacerbations (P = 0.73) or step‐up controller medication (P = 0.61). 
Discussion 
The goal of asthma treatment in pregnant women is to achieve control in order 
to prevent exacerbations, maintain maternal health and optimise fetal growth. 
Treatment should be adjusted to the lowest dose to maintain control. 
Despite the importance of adequate treatment16 and its safety, there is still 
interruption of treatment by pregnant women or by the clinicians who 
followed the pregnancies. In this series, nearly two‐thirds of the 14 pregnant 
asthmatics without medication reported fear of harm to the fetus as the reason 
for noncompliance and the remaining patients stopped treatment because of 
advice given by their attending physicians. 
Acid‐reflux symptoms are very frequent in pregnant women and they increase 
in severity during pregnancy. The pathophysiologic mechanisms involved in 
abnormal gastric reflux during pregnancy are decreased lower oesophageal 
sphincter pressure and alterations in gastrointestinal transit due to hormone 
changes, and increased intra‐abdominal pressure secondary to the enlarged 
gravid uterus. Asthma and gastro‐oesophageal reflux disease (GERD) are 
common comorbidities and the latest evidence‐based guidelines (GINA 2017) 
recommend that GERD should be treated in order to help reduce issues with 
asthma. However, published studies so far have not been conclusive as to the 
impact of treatment. There may be a connection between controlling GERD to 
aid in asthma control but high‐quality research to prove this is lacking. More 
robust research is required to establish or remove this link.10 Moreover, in 
this sample, acid reflux symptoms were not associated with asthma 
exacerbations and the need for step‐up of asthma medication. 
Allergic rhinitis is frequently associated with asthma and it may require the 
use of topical nasal corticosteroids and/or antihistamines. In this study, only 
14% of the pregnant women were medicated with nasal corticosteroids but 
74% resorted to antihistamines. 
Asthma in pregnancy should be monitored more regularly and this should 
include lung function evaluation, as recommended by the guidelines.3 In this 
sample, the mean %FEV1 throughout the evaluations remained above 80%. 
However, in the first evaluation, nearly 30% of the pregnant women had 
ventilatory obstructive defects, but none with severe obstruction or 
mixed/restrictive changes. This distribution of obstructive changes remained 
constant throughout the different assessments. 
In relation to CARAT (T), there was poor control in the first evaluation in 
almost 81% of the pregnant women, as well as CARAT (U) in 74% and 
CARAT (L) in 71% of the patients. There was a significant improvement in 
control for the three scores throughout the different assessments. These results 
may be related to better adherence to treatment and closer 
medical supervision. 
No significant correlation was found between CARAT scores and %FEV1. 
This correlation was weak in previous studies with CARAT14 and other 
asthma control questionnaires.17, 18 This may be explained by the sample 
size. 
However, significant negative correlations were detected between the CARAT 
(T) and CARAT (L) scores and the need for stepping up controller 
medication. 
In our opinion, these results support the combined use of CARAT and lung 
function tests in the clinical assessment of asthma during pregnancy, for closer 
monitoring and the evaluation of any necessary treatment adjustments. 
Conclusion 
The joint use of tools such as spirometry and validated questionnaires, 
particularly the CARAT, to objectively assess asthma control during 
pregnancy should be applied on a regular basis. The data presented in this 
study reinforces the importance of close monitoring of pregnant asthmatics in 
order to achieve and maintain control of the disease. 
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